FDA OKs Vascular Architects' clinical trial:
This article was originally published in Clinica
Vascular Architects has received a conditional approval from the US FDA to begin a multicentre clinical trial to test its aSpire covered stent as a treatment of superficial femoral and popliteal artery stenoses and occlusions. The VALIANT trial is a prospective, non-randomised study that will enrol up to 100 patients at 10 centres. It will assess the San Jose, California firm's stent and controlled expansion delivery system in patients in whom angioplasty has failed or produced suboptimal results. The stent and delivery system is already cleared in the US and in Europe for treating tracheobronchial strictures and peripheral vascular disease, respectively.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.